|
Acute kidney injury
|
0.200 |
Therapeutic
|
disease |
RGD |
N-acetylcysteine attenuates glycerol-induced acute kidney injury by regulating MAPKs and Bcl-2 family proteins.
|
20037173 |
2010 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
To explore the possibility that the genetic alterations of Bad might be involved in the development of human cancers, we analyzed the entire coding region and all splice sites of human Bad gene in 47 colon adenocarcinomas.
|
15033904 |
2004 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway.
|
21419810 |
2011 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.
|
30601084 |
2019 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, BAD expression in ATLL was slightly higher than ACs and HAM/TSPs and not significant.
|
30577817 |
2018 |
|
Aggressive Periodontitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The loss of BAD phosphorylation in the PPP-treated TP53 wild type cells further suggested that the treatment induced apoptosis through the BAD-mediated mitochondrial pathway.
|
24182354 |
2013 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition to increased B-cell lymphoma 2 (Bcl-2) phosphorylation through JNK signaling in response to docetaxel, si-Vav3 enhanced docetaxel-induced apoptosis, as characterized by the accumulation of sub-G1 phase cells and DNA fragmentation, through Bcl-xL/Bcl-2-associated death promoter (Bad) dephosphorylation, resulting in increased caspase-9, caspase-3, and cleaved poly(ADP-ribose) polymerase activation.
|
23566222 |
2013 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
LHGDN |
BCL10 gene amplification associated with strong nuclear BCL10 expression in a diffuse large B cell lymphoma with IGH-BCL2 fusion.
|
16785131 |
2006 |
|
B-Cell Lymphomas
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Western blot analysis was performed in order to determine the differential expression levels of Janus kinase (JAK), signal transducer and activator of transcription 3 (STAT3) and apoptosis associated proteins B-cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax) and Bcl-2 associated agonist of cell death (Bad).
|
28599489 |
2017 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
OGD/R-mediated DNA fragmentation and Casp3 expression could be prevented as well as resolved by the addition of hWJ-MSC-derived EV before and after OGD, respectively. hWJ-MSC-derived EV also tended to increase the phosphorylation of the B cell lymphoma 2 (Bcl2) family member Bcl-2-antagonist of cell death (BAD) in N2a cells, when added prior or post OGD, thereby inactivating the proapoptotic function of BAD.
|
29562785 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
GeneticVariation
|
group |
BEFREE |
We conclude that mutations in the BAD gene do not play a role in the pathogenesis of the major subtypes of human B-cell lymphomas.
|
16646081 |
2006 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Anti-apoptosis B-cell lymphoma (Bcl)-2 and Bcl-w genes were downregulated and pro-apoptotic Bcl-2-associated agonist of cell death and caspase-3 genes were upregulated in U-2OS cells following treatment with β-elemene-paclitaxel.
|
30008912 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Apoptosis was triggered through the intrinsic pathway by upregulating the expression of several B-cell lymphoma-2 (Bcl-2) family proapoptotic proteins, including p53-upregulated modulator of apoptosis (PUMA), Bcl-2-associated X protein and Bcl-2-associated agonist of cell death, and by downregulating the antiapoptotic protein Bcl-extra large.
|
28529565 |
2017 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
The apoptosis‑associated signaling showed that ursolic acid decreased the phosphorylation of AKT (Ser473) and B‑cell lymphoma 2 (Bcl‑2)‑associated agonist of cell death (BAD; Ser136), and the protein levels of Bcl‑2 and Bcl‑extra large (Bcl‑xL), and increased the expression of BAD and Bcl‑2‑associated X (Bax) protein in CAR cells.
|
29956797 |
2018 |
|
Benign melanocytic nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
RhoJ deletion in BRAF mutant melanocytes modulates the expression of the pro-apoptotic protein BAD as well as genes involved in cellular metabolism, impairing nevus formation, cellular transformation, and metastasis.
|
28753606 |
2017 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
Brachial Amyotrophic Diplegia
|
0.040 |
Biomarker
|
disease |
BEFREE |
DCT-induced PI3K/Akt activation resulted in downstream phosphorylation of GSK-3 (Ser(21/9)) and BAD (Ser(136)), and nuclear translocation (activation) of NF-kappaB, thereby confirming that DCT-induced activation of PI3K/Akt signaling regulates both proproliferative and prosurvival signals.
|
18064605 |
2008 |
|
Brachial Amyotrophic Diplegia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Study of the underlying mechanisms demonstrated alterations of molecular events involved in these processes, which included the activation of phosphoinositide 3-kinases (PI3K)/serine/threonine protein kinase B (PKB/AKT)/bcl-xL/bcl-2-associated death promoter homolog (Bad) signaling pathway, inhibition of caspase-3 activation, upregulation of Bcl-2, and downregulation of Bax.
|
21618708 |
2011 |
|
Brachial Amyotrophic Diplegia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The p-Akt (Ser473) was correlated with increased level of p-BAD (Ser136) (P = 0.012).
|
19882362 |
2010 |
|
Brachial Amyotrophic Diplegia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, knockdown of ICT1 altered signaling pathways associated with cell growth and apoptosis, including phospho‑BAD (Ser112), phospho-PRAS40 (Thr246) and induction of phospho‑AMPKα (Thr172).
|
28290601 |
2017 |
|
Brain Ischemia
|
0.200 |
Biomarker
|
disease |
RGD |
Melatonin attenuates the focal cerebral ischemic injury by inhibiting the dissociation of pBad from 14-3-3.
|
18078455 |
2008 |
|
Brain Ischemia
|
0.200 |
Biomarker
|
disease |
RGD |
Cluster analysis of mRNA expression levels identifies multiple sequential patterns following focal cerebral ischemia.
|
22843461 |
2012 |
|
Brain Stem Ischemia, Transient
|
0.300 |
Biomarker
|
disease |
CTD_human |
Overexpression of copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after transient focal ischemia by blocking activation of the Bad cell death signaling pathway.
|
12629175 |
2003 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the Akt phosphorylation and inactivation of its downstream target, BAD may play a role in survival of breast cancer cell.
|
19882362 |
2010 |